X0306 4 2016-02-03 1 0001432732 TriVascular Technologies, Inc. TRIV 0001457494 Delphi Management Partners VIII, L.L.C. 160 BOVET ROAD, SUITE 408 SAN MATEO CA 94402 0 0 1 0 0001457493 Delphi Management Partners VII, L.L.C. 160 BOVET ROAD, SUITE 408 SAN MATEO CA 94402 0 0 1 0 0001336922 DELPHI VENTURES VII L P C/O DELPHI VENTURES 160 BOVET ROAD, SUITE 408 SAN MATEO CA 94402 0 0 1 0 0001436285 DELPHI VENTURES VIII LP C/O DELPHI VENTURES 160 BOVET ROAD, SUITE 408 SAN MATEO CA 94402 0 0 1 0 0001346198 DELPHI BIOINVESTMENTS VII LP C/O DELPHI VENTURES 160 BOVET ROAD, SUITE 408 SAN MATEO CA 94402 0 0 1 0 0001451526 Delphi BioInvestments VIII LP C/O DELPHI VENTURES 160 BOVET ROAD, SUITE 408 SAN MATEO CA 94402 0 0 1 0 0001270735 ROEDER DOUGLAS A C/O DELPHI VENTURES 160 BOVET ROAD, SUITE 408 SAN MATEO CA 94402 1 0 1 0 0001255743 BOCHNOWSKI JAMES J C/O DELPHI VENTURES 160 BOVET ROAD, SUITE 408 SAN MATEO CA 94402 0 0 1 0 0001271389 DOUGLASS DAVID L C/O DELPHI VENTURES 160 BOVET ROAD, SUITE 408 SAN MATEO CA 94402 0 0 1 0 0001270734 PAKIANATHAN DEEPIKA C/O DELPHI VENTURES 160 BOVET ROAD, SUITE 408 SAN MATEO CA 94402 0 0 1 0 Common Stock 2016-02-03 4 U 0 3535910 D 0 I See Footnotes These shares were disposed of pursuant to the merger agreement between the Issuer and Endologix, Inc. ("Endologix") (such transaction, the "Merger"). In connection with the closing of the Merger, the Reporting Persons received 0.631 share of Endologix common stock and $0.34 in cash for each share of Issuer common stock held by such Reporting Persons, for a total consideration of $4.95 per share based upon the closing price of Endologix common stock on February 2, 2016. These securities were directly held as follows: 1,464,553 shares by Delphi Ventures VII, L.P. ("Ventures VII"), 14,641 shares by Delphi BioInvestments VII, L.P. ("BioInvestments VII" and together with Ventures VII, the "Delphi VII Funds"), 2,036,831 shares by Delphi Ventures VIII, L.P. ("Ventures VIII") and 19,885 shares by Delphi BioInvestments VIII, L.P. ("BioInvestments VIII" and together with Ventures VIII, the "Delphi VIII Funds" and collectively with the Delphi VII Funds, the "Delphi Funds"). Delphi Management Partners VII, L.L.C. ("DMP VII") is the general partner of each of Ventures VII and BioInvestments VII and may be deemed to have sole voting and dispositive power over the securities held by the Delphi VII Funds. Delphi Management Partners VIII, L.L.C. ("DMP VIII") is the general partner of each of Ventures VIII and BioInvestments VIII and may be deemed to have sole voting and dispositive power over the securities held by the Delphi VIII Funds. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of each of DMP VII and DMP VIII and may be deemed to share voting and dispositive power over the securities held by the Delphi Funds. Such persons and entities disclaim beneficial ownership of the securities held by the Delphi Funds, except to the extent of any pecuniary interest therein. In accordance with the terms of the merger agreement, Douglas A. Roeder resigned from his position as a member of the Issuer's Board of Directors, and any committees thereof, effective as of the closing of the Merger. /s/ Matthew T. Potter, Attorney-In-Fact for Delphi Management Partners VIII, L.L.C. 2016-02-04 Matthew T. Potter, Attorney-In-Fact for Delphi Management Partners VII, L.L.C. 2016-02-04 Matthew T. Potter, Attorney-In-Fact for Delphi Ventures VII, L.P. 2016-02-04 Matthew T. Potter, Attorney-In-Fact for Delphi Ventures VIII, L.P. 2016-02-04 Matthew T. Potter, Attorney-In-Fact for Delphi BioInvestments VII, L.P. 2016-02-04 Matthew T. Potter, Attorney-In-Fact for Delphi BioInvestments VIII, L.P. 2016-02-04 Matthew T. Potter, Attorney-In-Fact for Douglas A. Roeder 2016-02-04 Matthew T. Potter, Attorney-In-Fact for James J. Bochnowski 2016-02-04 Matthew T. Potter, Attorney-In-Fact for David L. Douglass 2016-02-04 Matthew T. Potter, Attorney-In-Fact for Deepika R. Pakianathan 2016-02-04